PDS Planning Inc Acquires New Shares in Kenvue Inc. (NYSE:KVUE)

PDS Planning Inc bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, Holdings Channel.com reports. The firm bought 12,331 shares of the company’s stock, valued at approximately $265,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Telemus Capital LLC lifted its holdings in Kenvue by 52.8% during the 4th quarter. Telemus Capital LLC now owns 54,259 shares of the company’s stock worth $1,168,000 after buying an additional 18,742 shares during the period. GUNN & Co INVESTMENT MANAGEMENT INC. lifted its holdings in Kenvue by 1,297.1% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 727,824 shares of the company’s stock worth $15,670,000 after buying an additional 675,728 shares during the period. OLD National Bancorp IN acquired a new position in Kenvue during the 4th quarter worth about $326,000. CWM LLC lifted its holdings in Kenvue by 142.8% during the 4th quarter. CWM LLC now owns 31,488 shares of the company’s stock worth $678,000 after buying an additional 18,519 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Kenvue by 20.0% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 164,176 shares of the company’s stock worth $3,535,000 after buying an additional 27,330 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research analyst reports. Royal Bank of Canada lowered their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. The Goldman Sachs Group assumed coverage on Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price for the company. Sanford C. Bernstein assumed coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. Finally, William Blair assumed coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $19.36 on Wednesday. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80. The stock’s 50 day moving average price is $19.84 and its 200-day moving average price is $20.15. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The business’s revenue was down 2.7% compared to the same quarter last year. As a group, equities analysts predict that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were issued a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 4.13%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.